Biotech Leader Testifies Before House Capital Markets Subcommittee

Washington, DC (May 23, 2018) – Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc., provided testimony today on behalf of the Biotechnology Innovation Organization (BIO) before the House of Representatives Committee on Financial Services, Subcommittee on Capital Markets, Securities, and Investment. Hahn serves as the Co-Chair of BIO’s Finance & Tax Committee.

Biotech in Our Backyard Panel to Highlight Agricultural Innovation in New England Region

Washington, D.C. (May 23, 2018) - Even with the abundance of high-profile international companies that will converge in Boston for the 2018 BIO International Convention, it’s difficult to overstate the work that is being done in Boston’s backyard. The New England region is one of the top life sciences clusters in the world, with Boston being home to many bioscience companies. 

BIO Written Testimony for House Financial Services Hearing on Legislative Proposals to Help Fuel Capital and Growth on Main Street

Good morning Chairman Huizenga, Ranking Member Maloney, and Members of the Capital Markets, Securities, and Investment Subcommittee. My name is Brian Hahn, and I am the Chief Financial Officer of GlycoMimetics, Inc., a 48-employee public biotech company based in Rockville, Maryland. I am also the Co-Chair of the Finance and Tax Committee at the Biotechnology Innovation Organization (BIO), which represents GlycoMimetics and over 1,100 other growth-stage biotechs that are driving the search for the next generation of cures and breakthrough medicines. The ability of growing businesses to access the public markets, as supported by the JOBS Act, is of paramount importance to biotechnology innovation because investment capital is the lifeblood of scientific advancement. It costs over $1 billion to develop a single life-saving treatment, and most companies spend more than a decade in the lab before their first therapy is approved. During this long development process, virtually every dollar spent by an emerging biotech comes directly from investors. Expenses ranging from buy-in-bulk beakers to $150 million clinical trials are all funded by investment capital because biotechs remain pre-revenue through their entire time in the lab and the clinic.

VirnetX Inc. v. The Mangrove Partners (Fed. Cir. 2018)

BIO and PhRMA have submitted a brief in the U.S Court of Appeals for the Federal Circuit on behalf of appellant in Virnetx Inc. v. The Mangrove Partners. 

BIO 2018 to Feature Rob Reiner as Keynote Speaker

Aactor, director and advocate Rob Reiner will deliver a keynote address at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7. Reiner’s family story of drug addiction reinforces the urgent need for biotechnology innovation in pain management

Food Evolution Writer/Producer Trace Sheehan to Keynote Food & Ag Program at BIO Int’l Convention

Washington, D.C. (May 16, 2018) – Trace Sheehan, writer and producer of the highly-acclaimed documentary film Food Evolution, will be a keynote speaker at BIO’s International Convention in Boston, the Biotechnology Innovation Organization (BIO) announced today.

BIO Statement on Trump Administration’s Plan to Lower Drug Costs

“We have concerns that some of the ideas proposed today could, if adopted, hurt patient access to the medicines they need …”

BIO’s Statement on PTO’s Proposed Changes to the Claim Construction Standard for PTAB Proceedings

Washington, D.C. (May 9, 2018) – Biotechnology Innovation Organization President for Advocacy, Law & Public Policy Tom DiLenge today issued the following statement in response to the U.S....

BIO Thanks President Trump for Rejecting RIN Cap, Supporting E15

BIO thanked President Trump and Senators Charles Grassley (R-IA) and Joni Ernst (R-IA) for rejecting a price cap on Renewable Identification Numbers (RINs) and working to provide regulatory relief to enable year-round sales of E15.

BIO Launches New Report Profiling 100 Renewable Chemical Technology Companies

BIO's new “Renewable Chemical Platforms Building the Biobased Economy” report documents the rapid expansion of renewable chemical platforms and applications around the world, profiling 100 companies from 16 countries that are commercializing renewable chemical applications.